ConMed (NSDQ:CNMD) reported second-quarter results that beat the consensus forecast on Wall Street. The Largo, Fla.–based surgical and patient monitoring products company posted profits of $13.3 million, or 41¢ per share, on sales of $255.2 million for the three months ended June 30, 2021. The results out yesterday evening showed a massively improving bottom line […]
BD begins remediation in Alaris infusion system software recall
BD (NYSE:BDX) announced today that it will begin remediation for a 2020 Class I-level recall of its Alaris infusion system. Franklin Lakes, N.J.–based BD has had shipments of Alaris pumps on hold after the FDA called for a comprehensive 510(k) submission to cover a host of software fixes, with pumps only going to health providers […]
FDA approves insulin glargine biosimilar injection from Viatris, Biocon Biologics
Viatris (NSDQ:VTRS) and Biocon Biologics announced FDA clearance for their Semglee insulin glargine-yfgn injection as a biosimilar. Semglee holds an indication for controlling high blood sugar in adults with type 2 diabetes and pediatric patients with type 1 diabetes. The FDA approved Semglee as the first interchangeable biosimilar product under the 351(k) regulatory pathway. The product is sold […]
West Pharmaceutial Services beats The Street, raises guidance
West Pharmaceutical Services (NYSE:WST) shares ticked up before hours on second-quarter results that beat the consensus forecast. The Exton, Pa.-based company posted profits of $187.3 million, or $2.47 per share, on sales of $723.6 million for the three months ended June 30, 2021, more than doubling its bottom-line on sales growth of 37.3%. Get the full […]
FDA clears Medtronic’s AI algorithms for cardiac monitoring
Medtronic (NYSE:MDT) announced today that the FDA cleared two of its AccuRhythm AI algorithms for use with the Linq II ICM. Fridley, Minn.–based Medtronic’s AccuRhythm AI applies artificial intelligence to heart rhythm event data collected by the Linq II insertable cardiac monitor (ICM) to improve the information provided to physicians for better diagnoses and treatments […]
Stryker has a Street-beating Q2, raises guidance
Stryker (NYSE:SYK) reported Q2 results that topped the consensus forecast as sales gained momentum during the previous easing of the COVID-19 pandemic. The Kalamazoo, Mich.–based orthopedic device giant posted profits of $592 million, or $1.55 per share, on sales of $4.3 billion for the three months ended June 30, 2021, marking a massive bottom-line gain […]
NeuroMetrix stock slides on publication of Quell study
NeuroMetrix (NSDQ:NURO) stock is hitting a massive skid this week after the publication of a study on its Quell non-invasive nerve stimulation device for pain relief. Shares of NURO were down -12.2% at $18.41 apiece by late-afternoon trading yesterday on the news. The stock continues to decline today, down –7.1% to $16.94 per share by […]
AliveCor, Acutus partner on remote monitoring pilot study
AliveCor and Acutus Medical (NSDQ:AFIB) today announced a collaboration to study the integration of data collection tools in cardiology. The companies plan to launch a post-market U.S. pilot study in the third quarter of 2021 to gain insights on how physicians can use AliveCor’s KardiaMobile electrocardiogram (ECG) device to facilitate pre-ablation and/or post-ablation remote monitoring […]
GE beats The Street as healthcare segment thrives in Q2
GE (NYSE:GE) shares ticked up today on second-quarter results that beat the consensus forecast. The Boston-based company’s healthcare segment posted profits of $801 million, registering a bottom-line gain of 58.3% year-over-year on sales of $4.5 billion — a 14% increase on revenues from the previous year. GE’s overall sales totaled $18.3 billion for the three […]
3M’s healthcare segment registers growth in Street-beating Q2
3M (NYSE:MMM) reported second-quarter results that beat the consensus forecast — with the company’s healthcare segment showing especially robust growth. The St. Paul, Minn.–based company posted profits of $1.5 billion, or $2.59 per share, on sales of $9 billion for the three months ended June 30, 2021, for a 16.7% bottom-line gain on sales growth […]
Boston Scientific rises on Street-beating Q2
Boston Scientific (NYSE:BSX) shares are up today on second-quarter results that topped the consensus forecast. The Marlborough, Mass.-based company posted profits of $172 million, or 12¢ per share, on sales of $3.1 billion for the three months ended June 30, 2021, marking a massive bottom-line gain from losses of $153 million this time last year. […]